Certificate Reference
For continuity with the current catalog, this page links to laboratory documentation for a component or a closely related product. The linked certificate is a reference only and is not represented as the batch-specific COA for PE-22-28.
Overview
PE-22-28 is a seven-amino-acid analog derived from spadin, an endogenous peptide associated with the sortilin/propeptide pathway. It was developed as a highly potent inhibitor of the TREK-1 two-pore-domain potassium channel, making it useful for ion-channel and neuroplasticity research.
Research Reference: View compound profile on NIH PubChem
Research Focus
WHAT THIS FORMULA FEATURES
Published work reported much higher affinity for TREK-1 than the parent spadin sequence, together with improved stability and rapid antidepressant-like activity in animal models. The experimental feature is therefore a small, channel-focused peptide rather than a broad neuromodulatory mixture.
EXPECTED RESEARCH READOUTS
Typical endpoints include TREK-1 current in patch-clamp assays, membrane excitability, downstream CREB or BDNF-related signaling, neurogenesis markers, and behavioral endpoints in validated preclinical models. Channel selectivity should be verified against related potassium channels.
Research endpoints described above reflect published or model-based scientific observations and are not guaranteed outcomes. This product is strictly for research purposes only. Not approved for human or animal use.
Key Characteristics
MOLECULAR PROFILE
Formula: C35H55N11O9
Weight: 773.9 g/mol
CAS: 1801959-12-5
PubChem CID: 165437303
Classification: Synthetic heptapeptide
Sequence: Gly-Val-Ser-Trp-Gly-Leu-Arg
PHYSICAL PROPERTIES
Form: Lyophilized powder
Catalog strengths: 10 mg
Purity specification: ≥99% catalog specification; verify current batch COA
Storage: Store at −20°C (−4°F) for long-term storage or 4°C (39°F) for short-term storage; avoid repeated freeze-thaw cycles.
Testing: Batch documentation should be verified against the current lot before analytical use.
